LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Finger Prick Blood Test to Enable Early Alzheimer’s Detection

By LabMedica International staff writers
Posted on 20 Nov 2024
Image: A quick finger prick and few drops of blood on a card could make Alzheimer’s testing more accessible (Photo courtesy of Shutterstock)
Image: A quick finger prick and few drops of blood on a card could make Alzheimer’s testing more accessible (Photo courtesy of Shutterstock)

A new approach using a quick finger prick and a few drops of blood on a card that can be sent in regular mail could make Alzheimer’s testing much more accessible worldwide. The new test involves collecting one or two drops of blood from a finger prick onto a special card that immediately separates the blood cells from the plasma. After about 15 minutes, once the card has dried, it is mailed to a laboratory where high-sensitivity techniques are used for analysis. The biomarkers used in this test have been developed over a long period and have demonstrated strong performance, first in cerebrospinal fluid, then in venous blood samples, and now in blood taken from superficial vessels in the finger.

The European study, led by researchers at the University of Gothenburg (Gothenburg, Sweden), included capillary blood samples from 203 participants who took the finger prick test at one of five memory clinics across Europe. The test kits were then mailed to the neurochemistry department at the University of Gothenburg, where biomarkers for Alzheimer’s, such as pTau217, were analyzed. This test could be available for use within a few years. Another European study is already in progress to assess whether the test can be self-administered, allowing individuals to perform the finger prick and send the sample to the lab without the need for healthcare personnel.

This development comes at a time when Alzheimer’s treatments are advancing, with the drug lecanemab already approved in several countries outside the EU. Early detection is crucial for the effectiveness of these treatments. The test may also open up new opportunities for research into Alzheimer’s disease, including its genetic profile and global prevalence. However, researchers stress that this test is not intended for widespread population screening. The World Health Organization (WHO) currently advises against general screening for Alzheimer’s disease, as treatment options have traditionally been limited, making such screenings ethically questionable.

“The simple capillary blood test works almost as well as venous samples, but unlike traditional blood tests, this new test does not require transport on dry ice,” said Hanna Huber, one of the study’s authors. “This could significantly increase accessibility to Alzheimer’s testing in countries and regions lacking the infrastructure needed for high-sensitivity analyses.”

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Gold Member
Hematology Analyzer
Medonic M32B

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more